Navigation Links
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Date:12/5/2012

JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23rd Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at 2:45 PM Eastern Time in New York and provide a business overview and update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun ... feet to its Welch Allyn campus. ... bring more than 100 new jobs to ... maintained a significant presence for more than 100 years. ... a large portion of which will be R&D and ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 2017  Getinge, a leading global provider of ... and cost efficiency within healthcare and life sciences, ... practice demonstrating that intra-aortic balloon counterpulsation (IABC) appears ... patients. The single-center, retrospective, observational study showed that ... ® 50cc intra-aortic balloon (IAB) in contemporary ...
Breaking Medicine Technology:
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
(Date:5/24/2017)... Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which the ... on the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and Clinical Integration company, announced today that its iClinic V12.2 solution has achieved ... Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based care with ...
(Date:5/23/2017)... ... 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations ... Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s ... ) today reported on a new study released on May 21, 2017 in the ...
Breaking Medicine News(10 mins):